1
Yves Ducharme, Jacques Y Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien: Phenyl heterocycles as cox-2 inhibitors. Merck Frosst Canada, Curtis C Panzer, David L Rose, December 12, 1995: US05474995 (196 worldwide citation)

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases, ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.


2
Jacques Y Gauthier, Cheuk K Lau, Yves LeBlanc, Chun Sing Li, Patrick Roy, Michel Therien, Zhaoyin Wang: Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents. Merck Frosst Canada, Curtis C Panzer, David L Rose, September 3, 1996: US05552422 (167 worldwide citation)

The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encomp ...


3
George Albers Schonberg, Hyman Wallick, Robert E Ormond, Thomas W Miller, Richard W Burg: Novel substances and process for their production. Merck & Co, David L Rose, Harry E Westlake, January 12, 1982: US04310519 (166 worldwide citation)

Novel compounds are produced by the fermentation of a nutrient medium with the previously undescribed microorganism Streptomyces avermitilis. They may be isolated by solvent extraction and chromatographic fractionation techniques. The compounds, which are described generically as C-076 have signific ...


4
Petpiboon Prasit, Daniel Guay, Zhaoyin Wang, Serge Leger, Michel Therien: Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2. Merck Frosst Canada, Curtis C Panzer, David L Rose, May 28, 1996: US05521213 (155 worldwide citation)

The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encomp ...


5
John C Chabala, Michael H Fisher: Selective hydrogenation products of C-076 compounds and derivatives thereof. Merck & Co, David L Rose, Harry E Westlake, April 22, 1980: US04199569 (153 worldwide citation)

Derivatives of C-076 are described in which the C-076 molecule, as series of macrolides, has a specific unsaturation, at the 22,23-position, catalytically reduced. Further reaction of the reduced C-076 compounds are also possible. The compounds thus produced have profound anthelmintic, insecticidal, ...


6
Yves Ducharme, Jacques Y Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien: Phenyl heterocycles as cox-2 inhibitors. Merck Frosst Canada, Curtis C Panzer, David L Rose, August 27, 1996: US05550142 (151 worldwide citation)

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.


7
Daniel Guay, Chun Sing Li: 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2. Merck Frosst Canada, Curtis C Panzer, David L Rose, February 18, 1997: US05604260 (149 worldwide citation)

The Compound of Formula I and pharmaceutically acceptable salts thereof in the treatment of cyclooxygenase-2 mediated diseases are disclosed.


8
Yves Ducharme, Jacques Y Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien: Phenyl heterocycles as COX-2 inhibitors. Merck Frosst Canada, Curtis C Panzer, David L Rose, July 16, 1996: US05536752 (148 worldwide citation)

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.


9
Cheuk K Lau, Cameron Black, Michel Belley: N-benzyl-3-indoleacetic acids as antiinflammatory drugs. Merck Frosst Canada, Curtis C Panzer, David L Rose, April 23, 1996: US05510368 (143 worldwide citation)

The invention encompasses the novel compound of Formula I as well as a method of treating inflammation and, in particular, cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. # ...


10
Cheuk Kun Lau, Cameron Black, Daniel Guay, Jacques Yves Gauthier, Yves LeBlanc, Patrick Roy, Yves Ducharme, Pierre Hamel: N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors. Merck Frosst Canada, Curtis C Panzer, David L Rose, June 17, 1997: US05639780 (140 worldwide citation)

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.